AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Aridis Pharmaceuticals Statistics
Share Statistics
Aridis Pharmaceuticals has 44.57M shares outstanding. The number of shares has increased by 0% in one year.
Shares Outstanding | 44.57M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 37.29M |
Failed to Deliver (FTD) Shares | 8.00K |
FTD / Avg. Volume | 48.46% |
Short Selling Information
The latest short interest is 2.00M, so 4.5% of the outstanding shares have been sold short.
Short Interest | 2.00M |
Short % of Shares Out | 4.5% |
Short % of Float | 5.37% |
Short Ratio (days to cover) | 0.22 |
Valuation Ratios
The PE ratio is -0.72 and the forward PE ratio is null.
PE Ratio | -0.72 |
Forward PE | null |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | -0.91 |
P/FCF Ratio | -0.76 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aridis Pharmaceuticals Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.32, with a Debt / Equity ratio of -0.18.
Current Ratio | 0.32 |
Quick Ratio | 0.32 |
Debt / Equity | -0.18 |
Total Debt / Capitalization | -21.57 |
Cash Flow / Debt | -6.77 |
Interest Coverage | -79.35 |
Financial Efficiency
Return on equity (ROE) is 1.27% and return on capital (ROIC) is 167.75%.
Return on Equity (ROE) | 1.27% |
Return on Assets (ROA) | -2.09% |
Return on Capital (ROIC) | 167.75% |
Revenue Per Employee | 0 |
Profits Per Employee | -831.05K |
Employee Count | 37 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 378.00K |
Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -26.04, so Aridis Pharmaceuticals 's price volatility has been lower than the market average.
Beta | -26.04 |
52-Week Price Change | null% |
50-Day Moving Average | 0 |
200-Day Moving Average | 0.03 |
Relative Strength Index (RSI) | 48.31 |
Average Volume (20 Days) | 16.51K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -29.99M |
Net Income | -30.75M |
EBITDA | -29.51M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.64 |
Balance Sheet
The company has 4.88M in cash and 6.13M in debt, giving a net cash position of -1.25M.
Cash & Cash Equivalents | 4.88M |
Total Debt | 6.13M |
Net Cash | -1.25M |
Retained Earnings | -195.67M |
Total Assets | 6.53M |
Working Capital | -13.37M |
Cash Flow
In the last 12 months, operating cash flow was -29.13M and capital expenditures -82.00K, giving a free cash flow of -29.21M.
Operating Cash Flow | -29.13M |
Capital Expenditures | -82.00K |
Free Cash Flow | -29.21M |
FCF Per Share | -1.56 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ARDS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | -655351.13% |
Analyst Forecast
Currently there are no analyst rating for ARDS.
Price Target | $2 |
Price Target Difference | n/a |
Analyst Consensus | Buy |
Analyst Count | 1 |
Scores
Altman Z-Score | -40.63 |
Piotroski F-Score | 4 |